Eli Lilly Files Lawsuits Over Illegal Retatrutide Sales

Eli Lilly and Company is intensifying its efforts to combat the unauthorized distribution of its drug retatrutide, filing six new lawsuits as part of this crackdown. The pharmaceutical giant is calling on various entities, including online marketplaces, payment companies, and regulatory bodies, to collaborate in shutting down the illegal black market for the medication. According to reports, Lilly's Chief Medical Officer has stated that retatrutide sold through illicit channels is "not a medicine," underscoring concerns about patient safety and product integrity.

In parallel, Eli Lilly has made a substantial investment in Absci Corporation, backing its program ABS-201 with US$40 million. This move has generated significant interest, with Absci's stock seeing a notable increase following the announcement. Further details regarding Absci's development and progress, including its Q2 2026 earnings, are also being reviewed by investors and analysts.

Separately, the company InduPro has announced the closure of a $77 million Series B financing round. InduPro has also dosed its first patient in a Phase 1 study for its lead oncology program, IDP-001. While not directly related to Lilly's current headline news, these developments contribute to the broader landscape of pharmaceutical innovation and investment.

This period of activity includes ongoing discussions and comparisons within the industry, such as analyses comparing Eli Lilly with competitor Novo Nordisk as potential investment opportunities. The company's multifaceted engagement across drug safety, strategic investments, and market positioning is drawing considerable attention.